{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:24:00Z","timestamp":1792423440250,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Li\u00e8ge and the F.R.S.-FNRS-T\u00e9l\u00e9vie","award":["7.4581.22"],"award-info":[{"award-number":["7.4581.22"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The protein tyrosine kinase-7 (PTK7) is an evolutionarily conserved transmembrane receptor that has emerged as a potential therapeutic target for human tumors. PTK7 is a pseudokinase that is involved in the modulation of the Wnt signaling pathway through interactions with other receptors. These interactions result in targeted gene activation that regulates cell polarity, migration, and proliferation during embryogenesis. Aside of this role during development, PTK7 has been shown as overexpressed in numerous cancers including colon carcinoma, leukemia, neuroblastoma, hepatoma, and ovarian cancer. The activity of PTK7 and the direct correlation with poor prognosis have fostered preclinical investigations and phase I clinical trials, aiming at inhibiting PTK7 and inducing antitumoral effects. In this review, we provide an exhaustive overview of the diverse approaches that use PTK7 as a new molecular target for cancer therapy in different tumor types. We discuss current therapies and future strategies including chimeric antigen receptor-T cells, antibody-drug conjugates, aptamers, based on up-to-date literature and ongoing research progress.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae290","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:05:04Z","timestamp":1730167504000},"source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7422-7887","authenticated-orcid":false,"given":"Kim","family":"Mottard","sequence":"first","affiliation":[{"name":"Laboratory of Nervous System Diseases and Therapy, GIGA Institute, University of Li\u00e8ge , 4000 Li\u00e8ge ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cokaiko","sequence":"additional","affiliation":[{"name":"Laboratory of Nervous System Diseases and Therapy, GIGA Institute, University of Li\u00e8ge , 4000 Li\u00e8ge ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rogister","sequence":"additional","affiliation":[{"name":"Laboratory of Nervous System Diseases and Therapy, GIGA Institute, University of Li\u00e8ge , 4000 Li\u00e8ge ,","place":["Belgium"]},{"name":"Neurology Department, University Hospital,\u00a0University of Li\u00e8ge , 4000 Li\u00e8ge ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-6579","authenticated-orcid":false,"given":"Virginie","family":"Neirinckx","sequence":"additional","affiliation":[{"name":"Laboratory of Nervous System Diseases and Therapy, GIGA Institute, University of Li\u00e8ge , 4000 Li\u00e8ge ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"2025082905215650300_CIT0001","first-page":"2179","article-title":"Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family","volume":"11","author":"Mossie","year":"1995","journal-title":"Oncogene"},{"key":"2025082905215650300_CIT0002","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"2025082905215650300_CIT0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2025082905215650300_CIT0004","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.molcel.2020.06.018","article-title":"Structural insights into pseudokinase domains of receptor tyrosine kinases","volume":"79","author":"Sheetz","year":"2020","journal-title":"Mol Cell"},{"key":"2025082905215650300_CIT0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/embor.2010.185","article-title":"Protein tyrosine kinase 7 has a conserved role in Wnt\/\u03b2-catenin canonical signalling","volume":"12","author":"Puppo","year":"2011","journal-title":"EMBO Rep"},{"key":"2025082905215650300_CIT0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature02677","article-title":"PTK7\/CCK-4 is a novel regulator of planar cell polarity in vertebrates","volume":"430","author":"Lu","year":"2004","journal-title":"Nature"},{"key":"2025082905215650300_CIT0007","doi-asserted-by":"crossref","first-page":"30562","DOI":"10.1074\/jbc.M115.697615","article-title":"The PTK7 and ROR2 protein receptors interact in the vertebrate WNT\/Planar cell polarity (PCP) pathway","volume":"290","author":"Martinez","year":"2015","journal-title":"J Biol Chem"},{"key":"2025082905215650300_CIT0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fcell.2017.00031","article-title":"PTK7 faces the Wnt in development and disease","volume":"5","author":"Berger","year":"2017","journal-title":"Front Cell Dev Biol"},{"key":"2025082905215650300_CIT0009","doi-asserted-by":"crossref","first-page":"101091","DOI":"10.1016\/j.xcrm.2023.101091","article-title":"Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma","volume":"4","author":"Lee","year":"2023","journal-title":"Cell Rep Med"},{"key":"2025082905215650300_CIT0010","doi-asserted-by":"crossref","first-page":"eaag2611","DOI":"10.1126\/scitranslmed.aag2611","article-title":"A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions","volume":"9","author":"Damelin","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025082905215650300_CIT0011","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/ijms23031295","article-title":"Whole-exome sequencing identifies a novel germline variant in PTK7 gene in familial colorectal cancer","volume":"23","author":"Miao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025082905215650300_CIT0012","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","article-title":"First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors","volume":"27","author":"Maitland","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025082905215650300_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05161-5","article-title":"Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention","volume":"13","author":"Raivola","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025082905215650300_CIT0014","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1158\/1078-0432.CCR-21-3078","article-title":"Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer","volume":"28","author":"Radovich","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025082905215650300_CIT0015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1535-7163.MCT-23-0164","article-title":"MTX-13, a Novel PTK7-directed antibody\u2013drug conjugate with widened therapeutic index shows sustained tumor regressions for a broader spectrum of PTK7-positive tumors","volume":"22","author":"Kong","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2025082905215650300_CIT0016","doi-asserted-by":"crossref","first-page":"665970","DOI":"10.3389\/fimmu.2021.665970","article-title":"PTK7-targeting CAR T-cells for the treatment of lung cancer and other malignancies","volume":"12","author":"Jie","year":"2021","journal-title":"Front Immunol"},{"key":"2025082905215650300_CIT0017","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-023-02084-9","article-title":"A novel TREM1\/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy","volume":"40","author":"Xu","year":"2023","journal-title":"Med Oncol"},{"key":"2025082905215650300_CIT0018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10611860903434050","article-title":"Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer","volume":"18","author":"Taghdisi","year":"2010","journal-title":"J Drug Target"},{"key":"2025082905215650300_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-022-00328-9","article-title":"Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate","volume":"26","author":"Xiang","year":"2022","journal-title":"Biomater Res"},{"key":"2025082905215650300_CIT0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/cancers15030922","article-title":"Targeted-lymphoma drug delivery system based on the Sgc8-c Aptamer","volume":"15","author":"Sicco","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025082905215650300_CIT0021","doi-asserted-by":"crossref","first-page":"e12566","DOI":"10.1111\/cpr.12566","article-title":"Effect of tetrahedral DNA nanostructures on proliferation and osteogenic differentiation of human periodontal ligament stem cells","volume":"52","author":"Zhou","year":"2019","journal-title":"Cell Prolif"},{"key":"2025082905215650300_CIT0022","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1021\/jacs.8b10795","article-title":"Engineering of bioinspired, size-controllable, self-degradable cancer-targeting DNA nanoflowers via the incorporation of an artificial sandwich base","volume":"141","author":"Zhang","year":"2019","journal-title":"J Am Chem Soc"},{"key":"2025082905215650300_CIT0023","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/nn201592s","article-title":"Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy","volume":"5","author":"Luo","year":"2011","journal-title":"ACS Nano"},{"key":"2025082905215650300_CIT0024","doi-asserted-by":"crossref","first-page":"102053","DOI":"10.1016\/j.nano.2019.102053","article-title":"Noncovalent tethering of nucleic acid aptamer on DNA nanostructure for targeted photo\/chemo\/gene therapies","volume":"24","author":"Shim","year":"2020","journal-title":"Nanomedicine"},{"key":"2025082905215650300_CIT0025","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1021\/acs.analchem.9b05878","article-title":"Improving tumor accumulation of aptamers by prolonged blood circulation","volume":"92","author":"Ding","year":"2020","journal-title":"Anal Chem"},{"key":"2025082905215650300_CIT0026","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1021\/acs.molpharmaceut.0c00335","article-title":"Aptamer-pyropheophorbide a conjugates with tumor spheroid targeting and penetration abilities for photodynamic therapy","volume":"17","author":"Xiong","year":"2020","journal-title":"Mol Pharm"},{"key":"2025082905215650300_CIT0027","doi-asserted-by":"crossref","first-page":"9316","DOI":"10.1021\/acsami.0c14730","article-title":"Aptamer-functionalized upconverting nanoformulations for light-switching cancer-specific recognition and in situ photodynamic-chemo sequential theranostics","volume":"13","author":"Jin","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"2025082905215650300_CIT0028","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1541-7786.MCR-16-0432","article-title":"Therapeutic targeting of PTK7 is cytotoxic in atypical teratoid rhabdoid tumors","volume":"15","author":"Messerli","year":"2017","journal-title":"MCR"},{"key":"2025082905215650300_CIT0029","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/acschembio.1c00826","article-title":"Discovery of small-molecule inhibitors of the PTK7\/\u03b2-catenin interaction targeting the Wnt signaling pathway in colorectal cancer","volume":"17","author":"Ganier","year":"2021","journal-title":"ACS Chem Biol"},{"key":"2025082905215650300_CIT0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-022-00001-9","article-title":"2021 FDA approvals","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025082905215650300_CIT0031","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther"},{"key":"2025082905215650300_CIT0032","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"2025082905215650300_CIT0033","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025082905215650300_CIT0034","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082905215650300_CIT0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025082905215650300_CIT0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025082905215650300_CIT0037","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"2025082905215650300_CIT0038","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science (New York, N.Y.)"},{"key":"2025082905215650300_CIT0039","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2025082905215650300_CIT0040","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/d41573-023-00148-z","article-title":"FDA approves second RNA aptamer","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2025082905215650300_CIT0041","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025082905215650300_CIT0042","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1073\/pnas.0602615103","article-title":"Aptamers evolved from live cells as effective molecular probes for cancer study","volume":"103","author":"Shangguan","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025082905215650300_CIT0043","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/pr700894d","article-title":"Cell-specific aptamer probes for membrane protein elucidation in cancer cells","volume":"7","author":"Shangguan","year":"2008","journal-title":"J Proteome Res"},{"key":"2025082905215650300_CIT0044","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/10717544.2017.1373166","article-title":"Development of DNA tetrahedron-based drug delivery system","volume":"24","author":"Hu","year":"2017","journal-title":"Drug Deliv"},{"key":"2025082905215650300_CIT0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tibtech.2022.08.011","article-title":"Novel DNA nanoflower biosensing technologies towards next-generation molecular diagnostics","volume":"41","author":"Sheng","year":"2023","journal-title":"Trends Biotechnol"},{"key":"2025082905215650300_CIT0046","first-page":"A1282","article-title":"1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts","volume":"11","author":"Yao","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"2025082905215650300_CIT0047","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2020-0163","article-title":"TROPiCS-02: a phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2-metastatic breast cancer","volume":"16","author":"Rugo","year":"2020","journal-title":"Future Oncol"},{"key":"2025082905215650300_CIT0048","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/acsptsci.1c00188","article-title":"Enhancing CAR-T cell therapy with functional nucleic acids","volume":"4","author":"Maru","year":"2021","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae290\/60183679\/oyae290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae290\/60183679\/oyae290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:22:10Z","timestamp":1756459330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae290\/7848503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae290","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,10,28]]},"article-number":"oyae290"}}